Polyrizon Ltd.
PLRZ · Surgical & Medical Instruments & Apparatus · EDGAR filings ↗
Reference price $11.85 — last insider sale, 2026-03-31 (estimated from the dated SEC Form 4 price — not a live quote)
Grade
D42Pre-revenue, pre-clinical micro-cap biotech near cash-out with serial reverse splits.
Strengths
- High headline current/quick ratio (29, 99th pct) on a small liability base
- Net loss growth optics (88th pct) and lead C&C program advancing toward a 2026 trial
Risks
- Only $1.3M cash and ~1.2-quarter runway (15th pct) — imminent funding need or curtailment
- Two reverse splits in 2025, no revenue, unproven novel platforms and pivotal-trial inexperience
Notable findings
- Cash burnNegative free cash flow (-4.5M)
- Insider sellingInsider selling — 6 open-market sale(s) by 4 insider(s) (cluster of 4 insiders, last 6mo) Form 4 ↗
Key metrics
Return on equity
-15.9%
Return on assets
-15.6%
Current ratio
29.0×
Free cash flow
-$5M
Tangible book value
$18M
Cash & investments
$1M
Cash runway
1q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-31 | Izraeli Tomer | Sell | 500 | $11.85 |
| 2026-03-31 | Carmel Liron | Sell | 942 | $12.36 |
| 2026-03-31 | Adler Oz | Sell | 3.3K | $12.05 |
| 2026-03-30 | Carmel Liron | Sell | 100 | $11.00 |
| 2026-03-30 | Izraeli Tomer | Sell | 3.9K | $10.90 |
| 2026-03-30 | Turgeman Tidhar | Sell | 2.9K | $10.90 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07588672 ↗ | Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis | NA | Not Yet Recruiting | 2027-07-15 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-25 | 2025-12-31 | 0001213900-26-034198 ↗ |
| 20-F | 2025-03-11 | 2024-12-31 | 0001213900-25-022732 ↗ |